Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders
Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose. Immunization with opioid-based haptens conjugated to immunogenic carriers elicits opioid-specific antibodie...
Saved in:
Main Authors: | Christine Robinson (Author), Carly Baehr (Author), Shirdi E. Schmiel (Author), Claudia Accetturo (Author), Daniel L. Mueller (Author), Marco Pravetoni (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunology and efficacy of MF59-adjuvanted vaccines
by: Eun-Ju Ko, et al.
Published: (2018) -
Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine
by: Alireza Loghmani, et al.
Published: (2020) -
Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines
by: Erman Tritama, et al.
Published: (2018) -
Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
by: Daniela Amicizia, et al.
Published: (2023) -
Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant
by: L. Punzi, et al.
Published: (2012)